Document is current
Any future updates will be listed below
-
Authors
Morgans, Alicia K. https://orcid.org/0000-0002-6563-4587
Wallis, Christopher J. D.
Halabi, Susan https://orcid.org/0000-0003-4135-2777
Armstrong, Andrew J. https://orcid.org/0000-0001-7012-1754
Adorjan, Patrick
Ghadessi, Mercedeh
Verholen, Frank
Grimm, Marc-Oliver
-
Funding
Funding for this research was provided by:
The ARAMIS study was funded by Bayer AG and Orion Pharma
- License Information
-
More Information
Article History
Received: 18 June 2025
Revised: 16 December 2025
Accepted: 19 January 2026
First Online: 12 February 2026
Competing interests
: AM: Consulting or advisory role: Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, BMS, Bayer, Curium, Exact Sciences, Exelixis, Inc., Janssen, Lantheus Medical Imaging, Macrogenics, Merck, Novartis, Pfizer, Sanofi, Sumitomo Pharma, Telix Pharmaceuticals, Tolmar; Honoraria: Advanced Accelerator Applications, Astellas Scientific and Medical Affairs Inc., AstraZeneca, Bayer, Curium Pharma, Janssen, Janssen Oncology, Merck, Novartis, Pfizer, Telix Pharmaceuticals; Research funding: Astellas Scientific and Medical Affairs Inc., Bayer, Janssen, Pfizer, Seattle Genetics/Astellas; Travel, accommodations, expenses: Bayer, Pfizer; Stock and other ownership: Vertex. CJDW: Consulting fees: Janssen Oncology, Nanostics Inc, Precision Point Specialty LLC, SESEN Bio; Honoraria/travel: AbbVie, Astellas, Astra Zeneca, Bayer, EMD Serono, Haymarket Media, Healing and Cancer Foundation, Knight Therapeutics, Merck, Science & Medicine Canada, TerSera Canada, Tolmar Pharmaceuticals Canada; Research funding: Bayer, Knight Therapeutics, Tolmar Pharmaceuticals. SH: Employment: American Society for Clinical Oncology (ASCO); Honoraria: AVEO Oncology, Beigene, Bristol Myers Squibb, CG Oncology, Janssen, Sanofi. AJA: Consulting or advisory role: Astellas Scientific and Medical Affairs Inc, AstraZeneca, Bayer, Bristol-Myers Squibb, Epic Sciences, Exelixis, FORMA Therapeutics, GoodRx, IDEAYA Biosciences, Janssen, Merck, Myovant Sciences, Novartis, Pfizer; Research funding: Amgen (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), BeiGene (Inst), Bristol-Myers Squibb (Inst), Bristol-Myers Squibb (Inst), Constellation Pharmaceuticals (Inst), Dendreon (Inst), FORMA Therapeutics (Inst), Gilead Sciences (Inst), Janssen Oncology (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Roche/Genentech (Inst); Patents, royalties, other intellectual property: Circulating tumor cell novel capture technology (Inst); Travel, accommodations, expenses: Astellas Scientific and Medical Affairs Inc. PA: Employment: Bayer. MG: Employment: Bayer. FV: Employment: Bayer. MOG: Research funding: Bayer Vital, BMS, Intuitive Surgical; Consulting/advisory role: Astellas, AstraZeneca, Bayer Vital, BMS, Eisai, EUSA Pharma, Gilead, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Roche Pharma AG, Takeda.
